• PFHxS Hepatotoxicity and PPAR Signaling in Zebrafish

  2026-09-26

  This study combines transcriptomic screening with liver pathology, biochemical measurements, and targeted intervention to show that environmentally relevant PFHxS exposure can impair liver development and function in larval zebrafish. Antagonist treatment and PPAR knockdown alleviated several hepatic effects, strengthening the case for PPAR signaling as a contributor while leaving the responsible receptor subtype and human relevance open for further testing.

• SGC-CBP30: Practical Guide to Cell Assays

  2026-09-25

  A scenario-driven guide to using SGC-CBP30 (SKU A4491), a CREBBP/EP300 bromodomain inhibitor, in cell viability and transcriptional studies. It covers assay design, handling, interpretation, and how to evaluate the evidence when extending epigenetics research into lung adenocarcinoma models.

• Camostat Mesilate: From Protease Probe to Pathway Logic

  2026-09-25

  Camostat Mesilate is a trypsin-like protease inhibitor used to investigate epithelial ion-channel regulation and fibrotic signaling. This article explains how to interpret its effects as pathway evidence, and how a distinct structure-guided antiviral study sharpens decisions about choosing the right type of molecular perturbation.

• Anagliptin Vasorelaxation: Kv Channels and SERCA

  2026-09-24

  A 2025 study found that anagliptin relaxed phenylephrine-contracted rabbit aortic rings, with inhibitor experiments implicating voltage-dependent potassium channels and the SERCA pump. The findings identify a vascular action worth investigating alongside DPP-4 inhibition, while leaving the molecular targets and relevance to intact organisms unresolved.

• Regorafenib (BAY 73-4506): Research Evidence

  2026-09-24

  Regorafenib (BAY 73-4506) is a multikinase inhibitor used to investigate angiogenesis and tumor signaling. A 2024 melanoma study links its antitumor effects to reduced RRM2 and altered ERK/E2F3 signaling, while the available evidence does not establish direct binding to RRM2.

• Sisomicin Assays: From MIC to Mechanism

  2026-09-23

  Sisomicin is an aminoglycoside antibiotic whose activity depends on both bacterial susceptibility and assay context. This guide connects its 30S-ribosome mechanism, resistance phenotypes, and practical in vitro testing choices to help researchers interpret results more rigorously.

• Ultrasound Nanoparticles for Lung Cancer Therapy

  2026-09-23

  The reference study develops M@DRSZ, a pH-sensitive, tumor-membrane-coated nanoparticle that combines doxorubicin delivery, nitric oxide release, sonodynamic therapy, and homologous targeting. Its ultrasound-triggered ROS/RNS chemistry is reported to generate peroxynitrite, damage tumor-cell organelles, promote apoptosis, and reshape antitumor immunity in A549 models.

• Lenalidomide and DOT1L: Rewiring Myeloma Immunity

  2026-09-22

  Lenalidomide is more than a conventional immunomodulatory drug in multiple myeloma research. Emerging evidence shows that DOT1L inhibition can activate STING-linked innate immune signaling, suppress IRF4–MYC transcriptional dependencies, and strengthen lenalidomide-responsive programs—creating a practical framework for mechanism-driven combination studies.

• Firefly Luciferase mRNA Workflow Guide

  2026-09-22

  Build sensitive reporter assays with Cap1-capped, 5-moUTP modified mRNA for rapid protein expression, delivery benchmarking, and in vivo imaging. The workflow combines controlled RNA handling with formulation-aware optimization inspired by current lipid nanoparticle research.

• Mitochondrial Calcium Signaling Represses Ferroptosis

  2026-09-21

  The reference study identifies a mechanistic link between mitochondrial calcium uptake, acetyl-CoA-dependent GPX4 modification, and suppression of ferroptotic cell death. Its genetic rescue, mutational, structural, and tumor-model evidence positions mitochondrial calcium signaling as a metabolic regulator of ferroptosis resistance, while also defining important limits for translating the findings into metabolism-focused cancer assays.

• TG003 Cdc2-like Kinase Inhibitor Guide

  2026-09-21

  TG003 is a potent Cdc2-like kinase inhibitor that preferentially inhibits Clk1, Clk2, and Clk4 in reported biochemical assays. It provides a research tool for alternative splicing modulation, serine/arginine-rich protein phosphorylation studies, splice site selection research, and exon-skipping therapy models.

• Aminopeptidase Selectivity and ACE Inhibitor Action

  2026-09-20

  The 1992 study by Tieku and Hooper re-evaluated how bestatin and structurally distinct metallopeptidase inhibitors affect three porcine kidney aminopeptidases. Its central contribution was to show that inhibitor class strongly influences selectivity: conventional carboxyalkyl and phosphoryl ACE inhibitors spared AP-A, AP-N, and AP-W, whereas several sulfhydryl ACE inhibitors inhibited AP-W.

• Dynasore Workflows for Endocytosis Research

  2026-09-19

  Dynasore is a reversible, cell-permeable dynamin GTPase inhibitor for separating dynamin-dependent uptake from parallel internalization routes. This guide translates infection-model evidence into practical workflows for endocytosis research, synaptic vesicle studies, trafficking assays, and pathway troubleshooting.

• Cyclopamine: From Hedgehog Biology to PTC Translation

  2026-09-18

  Cyclopamine is more than a Hedgehog pathway probe: emerging papillary thyroid carcinoma data connect Smoothened inhibition with APOC1-dependent tumor biology. This translational perspective examines mechanism, validation strategy, formulation, developmental liabilities, and the path from pathway perturbation to biomarker-informed cancer research.

• N-MYC–eIF4G1 Survival Axis in inv(16) AML

  2026-09-18

  Peramangalam and colleagues identify a previously unrecognized MYCN enhancer and define eIF4G1 as a downstream survival effector in inv(16) acute myeloid leukemia. By integrating transcriptomic analysis, regulatory-element studies, leukemia models, and patient-derived xenografts, the study provides a mechanistic framework for understanding how N-MYC sustains this AML subtype.

7965 records 1/531 page Next 12345 下5页 Last page